Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US

Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US

Abstract Background A significant minority of asthma patients remain uncontrolled despite the use of inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA). A number of add-on therapies, including monoclonal antibodies (namely omalizumab) and more recently tiotropium bromide have been re...

Full description

Bibliographic Details
Main Authors: Zafar Zafari, Mohsen Sadatsafavi, J. Mark FitzGerald, for the Canadian Respiratory Research Network
Format: Article
Language:English
Published: BMC 2018-01-01
Series:Cost Effectiveness and Resource Allocation
Subjects:
Tiotropium
Omalizumab
Uncontrolled asthma
Cost-effectiveness analysis
Decision analysis
Markov model
Online Access:http://link.springer.com/article/10.1186/s12962-018-0089-8

Internet

http://link.springer.com/article/10.1186/s12962-018-0089-8

Similar Items